Wednesday, 29 November 2017

Orphan Drug Status for BXQ-350

FDA granted Bexion Orphan Drug status for Saposin C, the active ingredient in its proprietary drug BXQ-350, for the potential treatment of glioblastoma.  http://bit.ly/2AlVuGb

No comments:

Post a Comment